Figure 3 - uploaded by Young Jeung Park
Content may be subject to copyright.
Left column (A, B: Limbal-conjunctival autograft without 0.02% MMC, C, D: Limbal-conjunctival autograft with 0.02% MMC) Images of preoperative fleshy grade 3 nasal primary pterygium. Right column (E, F: Limbal- conjunctival autograft without 0.02% MMC, G, H: Limbal-conjunctival autograft with 0.02% MMC) Images of the LCAT of the same patients 6 months after the surgery. Well-positioned graft and reestablishment of the normal limbal architecture are observed with no signs of recurrences in all subjects. Notice: The lack of scar on the donor and recipient conjunctiva due to the use of bioadhesives, and the cosmetic advantage due to appropriate size of conjuctival flap after extensive pterygium excision are apparent.
Source publication
To evaluate the effectiveness of Mitomycin C used as a combined therapy along with limbal-conjunctival autograft for primary pterygium.
Similar publications
A 40-year-old woman visited our clinic for recurred pterygium and symblepharon in the right eye. She had a history of pterygium excision 8 years before. Over the course of 7 years, we performed pterygium excision combined initially with mitomycin C (MMC) application and conjunctival autograft. This was followed by three procedures using limbal allo...
Pterygium is a cause of diminution of vision when it encroaches on the pupillary area. It typically develops in patients who have been living in hot climates and may represent a response to chronic dryness and exposure to ultraviolet light, dust and hot winds. It is rarely seen in patients younger than the age of 20 years. The study was conducted t...
Introduction: High recurrence of a fibrotic disease, pterygium, following the surgical procedure is perceived as the primary challenge of its management. As the standard procedure, adjuvant therapy of using mitomycin C could dramatically reduce the recurrence of pterygium but could cause multiple serious complications. Our study aimed to investigat...
Introduction: Various pro-inflammatory cytokines and growth factors have been implicated in the pathogenesis of pterygium (Pt); however, the effect of cytokines produced by helper T lymphocytes (Th) has been poorly studied. To date, only interleukin 4 (IL-4) from Th lymphocytes has been linked to Pt recurrence. Therefore, this study aimed to evalua...
Aim: The aim is to study the management of primary pterygium by surgical excision with sutureless conjunctival autograft with limbal stem cells. Materials and Methods: Patients with advanced pterygium were recruited from eye outpatient department (OPD) of rural tertiary care hospital of central India from January 2016 to October 2016. Informed writ...
Citations
Purpose: We evaluated a combination of intraoperative mitomycin C (MMC) and amniotic membrane transplantation (AMT) for treating recurrent pterygia. Methods: We retrospectively analyzed 40 eyes of 39 patients with recurrent pterygia who underwent AMT from December 2007 to July 2015 and who were followed-up for a minimum of 12 months. In all, 22 eyes received intraoperative MMC (group A) and 18 did not (group B). Recurrence rates and complications were compared between the two groups. Results: Conjunctival recurrence was noted in two and corneal recurrence was noted in four eyes of group A (27.3%); the figures for group B were four and three (38.9%). These recurrence rates were not significantly different (p = 0.545). In five cases with preoperative symblepharon, this condition recurred when MMC was not used (two eyes) but not when MMC was used (three eyes). No major complications such as necrotizing scleritis, scleromalacia, or corneal ulcer were observed in either group after surgery. Conclusions: Intraoperative adjunct MMC therapy did not significantly inhibit recurrence after AMT for treating recurrent pterygia but may reduce the recurrence rate of symblepharon. 2018 The Korean Ophthalmological Society.
To compare postoperative recurrence rates of pterygium surgery with amniotic membrane transplantation with and without mitomycin C.
